{"id":"vitamin-k-antagonist-vka","safety":{"drugInteractions":[{"drug":"Amiodarone","action":"Monitor","effect":"Increased INR"},{"drug":"Aspirin","action":"Monitor","effect":"Increased INR"},{"drug":"Azithromycin","action":"Monitor","effect":"Increased INR"},{"drug":"Cimetidine","action":"Monitor","effect":"Increased INR"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased INR"},{"drug":"Diltiazem","action":"Monitor","effect":"Increased INR"},{"drug":"Erythromycin","action":"Monitor","effect":"Increased INR"},{"drug":"Fluconazole","action":"Monitor","effect":"Increased INR"},{"drug":"Fluoxetine","action":"Monitor","effect":"Increased INR"},{"drug":"Isoniazid","action":"Monitor","effect":"Increased INR"},{"drug":"Ketoconazole","action":"Monitor","effect":"Increased INR"},{"drug":"Metronidazole","action":"Monitor","effect":"Increased INR"},{"drug":"Omeprazole","action":"Monitor","effect":"Increased INR"},{"drug":"Rifampicin","action":"Avoid","effect":"Decreased INR"},{"drug":"Sulfinpyrazone","action":"Avoid","effect":"Decreased INR"},{"drug":"Tetracycline","action":"Monitor","effect":"Increased INR"},{"drug":"Verapamil","action":"Monitor","effect":"Increased INR"}],"contraindications":["Hypersensitivity to the drug or any of its components","Severe liver disease with coagulopathy and risk of bleeding","Uncontrolled hypertension","Active bleeding","Pregnancy, especially in the first trimester due to teratogenic effects","Conditions with a high risk of bleeding, such as recent surgery or trauma","Concomitant use of other anticoagulants unless under strict medical supervision"]},"trials":["NCT06521463","NCT04618913","NCT05038228","NCT05825573","NCT04045665","NCT06315530","NCT05646394","NCT04284839","NCT07125417","NCT07011095","NCT06429787","NCT02798471","NCT03892824","NCT02618577","NCT06747312","NCT04062097","NCT02886962","NCT06143787","NCT04249401","NCT04001205","NCT05205863","NCT06179823","NCT05150938","NCT03826927","NCT02533960","NCT04195113","NCT04002011","NCT02740335","NCT02353585","NCT02664155","NCT02832544","NCT02981472","NCT04171726","NCT02832531","NCT02663076","NCT02640222","NCT02507856","NCT02286414","NCT03362788","NCT02319460","NCT04099238","NCT04518735","NCT03150303","NCT03374540","NCT04419012","NCT03537521","NCT01722786","NCT02415400","NCT02866175","NCT02596230","NCT04117048","NCT02234843","NCT02556203","NCT02839746","NCT02942576","NCT02684981","NCT02849509","NCT04007653","NCT02610153","NCT02240667","NCT02072434","NCT02597920","NCT03580577","NCT03087474","NCT03462446","NCT02227550","NCT01830543","NCT03276377","NCT02376777","NCT02687854","NCT02690155","NCT02687867","NCT01729871","NCT01029743","NCT02090543","NCT02427516","NCT02906527","NCT02657616","NCT02485873","NCT01674647","NCT00395772","NCT01533441","NCT00439777","NCT00440193","NCT00645853","NCT00623779","NCT00067093","NCT00062803"],"company":"Pfizer Inc.","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=vitamin-k-antagonist-vka","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-05-15T02:30:48.577382+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-05-14T02:29:30.821620+00:00"}},"allNames":"vitamin k antagonist (vka)","timeline":[],"aiSummary":"Pfizer Inc. is developing a Vitamin K antagonist (VKA) in the preclinical phase for the prophylaxis and treatment of venous thrombosis and thromboembolism. The key competitive advantage of VKAs lies in their well-established mechanism for preventing blood clots, though the specific mechanism of Pfizer's VKA is not detailed. Primary risks include strong competition from established anticoagulants such as Dabigatran, Rivaroxaban, Apixaban, and Betrixaban.","brandName":"Vitamin K antagonist (VKA)","isGeneric":true,"mechanism":{"target":"Vitamin K-dependent clotting factors","novelty":"Me-too","modality":"Small molecule","drugClass":"Anticoagulant","explanation":"","oneSentence":"","technicalDetail":"Vitamin K antagonist (VKA) inhibits the gamma-carboxylation of vitamin K-dependent clotting factors, which are essential for blood coagulation. This results in a decrease in the production of these clotting factors, leading to a reduction in blood clot formation. The exact molecular mechanism of action of Vitamin K antagonist (VKA) is not fully understood."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=vitamin-k-antagonist-vka","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=vitamin-k-antagonist-vka","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-05-15T02:30:48.577578+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"competitors":[{"name":"Pradaxa","company":"Boehringer Ingelheim","advantage":"Direct oral anticoagulant, no need for regular blood monitoring","genericName":"Dabigatran"},{"name":"Xarelto","company":"Janssen Pharmaceuticals","advantage":"Direct oral anticoagulant, convenient dosing regimen","genericName":"Rivaroxaban"},{"name":"Eliquis","company":"Pfizer","advantage":"Direct oral anticoagulant, low risk of bleeding","genericName":"Apixaban"},{"name":"Beyfortis","company":"Portola Pharmaceuticals","advantage":"Longer duration of action, reduced need for frequent dosing","genericName":"Betrixaban"}],"genericName":"vitamin-k-antagonist-vka","indications":{"approved":[{"name":"Prophylaxis and treatment of venous thrombosis and thromboembolism","regulator":"FDA"},{"name":"Prophylaxis and treatment of pulmonary embolism","regulator":"FDA"},{"name":"Prophylaxis and treatment of deep vein thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of myocardial infarction","regulator":"FDA"},{"name":"Prophylaxis and treatment of stroke","regulator":"FDA"},{"name":"Prophylaxis and treatment of atrial fibrillation","regulator":"FDA"},{"name":"Prophylaxis and treatment of mechanical heart valves","regulator":"FDA"},{"name":"Prophylaxis and treatment of warfarin-induced skin necrosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of coumarin-induced skin necrosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of antiphospholipid syndrome","regulator":"FDA"},{"name":"Prophylaxis and treatment of heparin-induced thrombocytopenia","regulator":"FDA"},{"name":"Prophylaxis and treatment of cancer-associated thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of postoperative thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent venous thromboembolism","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent pulmonary embolism","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent deep vein thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent myocardial infarction","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent stroke","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent atrial fibrillation","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent mechanical heart valves","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent warfarin-induced skin necrosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent coumarin-induced skin necrosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent antiphospholipid syndrome","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent heparin-induced thrombocytopenia","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent cancer-associated thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent postoperative thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent recurrent venous thromboembolism","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent recurrent pulmonary embolism","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent recurrent deep vein thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent recurrent myocardial infarction","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent recurrent stroke","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent recurrent atrial fibrillation","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent recurrent mechanical heart valves","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent recurrent warfarin-induced skin necrosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent recurrent coumarin-induced skin necrosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent recurrent antiphospholipid syndrome","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent recurrent heparin-induced thrombocytopenia","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent recurrent cancer-associated thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of recurrent recurrent postoperative thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to warfarin therapy","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to coumarin therapy","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to heparin therapy","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to antithrombin therapy","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to thrombin inhibitors","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to factor Xa inhibitors","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to direct oral anticoagulants","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with atrial fibrillation","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with mechanical heart valves","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with cancer","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with heparin-induced thrombocytopenia","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with antiphospholipid syndrome","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with postoperative thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent venous thromboembolism","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent pulmonary embolism","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent deep vein thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent myocardial infarction","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent stroke","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent atrial fibrillation","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent mechanical heart valves","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent warfarin-induced skin necrosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent coumarin-induced skin necrosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent antiphospholipid syndrome","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent heparin-induced thrombocytopenia","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent cancer-associated thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent postoperative thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent venous thromboembolism","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent pulmonary embolism","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent deep vein thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent myocardial infarction","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent stroke","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent atrial fibrillation","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent mechanical heart valves","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent warfarin-induced skin necrosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent coumarin-induced skin necrosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent antiphospholipid syndrome","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent heparin-induced thrombocytopenia","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent cancer-associated thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent postoperative thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent recurrent venous thromboembolism","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent recurrent pulmonary embolism","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent recurrent deep vein thrombosis","regulator":"FDA"},{"name":"Prophylaxis and treatment of bleeding due to anticoagulant therapy in patients with recurrent recurrent recurrent myocardial infarction","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"trialDetails":[{"nctId":"NCT06521463","phase":"NA","title":"SIMPLAAFY Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","isPivotal":false,"enrollment":1857,"indication":"Atrial Fibrillation, Stroke","completionDate":"2027-01","primaryEndpoint":""},{"nctId":"NCT04618913","phase":"","title":"Anticoagulation in Patients With Venous Thromboembolism and Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","isPivotal":false,"enrollment":1,"indication":"Neoplasms, Embolism","completionDate":"2026-04-06","primaryEndpoint":""},{"nctId":"NCT05038228","phase":"","title":"High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","isPivotal":false,"enrollment":1,"indication":"Atrial Fibrillation","completionDate":"2026-04-08","primaryEndpoint":""},{"nctId":"NCT05825573","phase":"PHASE3","title":"Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","isPivotal":false,"enrollment":340,"indication":"Intracardiac Thrombus, STEMI","completionDate":"2026-02","primaryEndpoint":""},{"nctId":"NCT04045665","phase":"PHASE3","title":"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","isPivotal":false,"enrollment":3200,"indication":"Atrial Fibrillation, Stroke","completionDate":"2026-08-31","primaryEndpoint":""},{"nctId":"NCT06315530","phase":"PHASE2","title":"Effect of Telitacicept on Antibody Titers in Primary APS Patients","status":"COMPLETED","sponsor":"Ruijin Hospital","isPivotal":false,"enrollment":20,"indication":"Antiphospholipid Syndrome (APS)","completionDate":"2026-01-06","primaryEndpoint":""},{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","isPivotal":false,"enrollment":150,"indication":"Antiphospholipid Syndrome, Arterial Thrombosis","completionDate":"2029-12-31","primaryEndpoint":""},{"nctId":"NCT04284839","phase":"PHASE3","title":"The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","isPivotal":false,"enrollment":3500,"indication":"Bleeding Post Cardiac Surgery, Indication for Anticoagulation","completionDate":"2027-06","primaryEndpoint":""},{"nctId":"NCT07125417","phase":"PHASE4","title":"Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure","status":"RECRUITING","sponsor":"OCEAN-SHD Study Group","isPivotal":false,"enrollment":500,"indication":"Nonvalvular Atrial Fibrillation, Aspirin","completionDate":"2030-03-31","primaryEndpoint":""},{"nctId":"NCT07011095","phase":"EARLY_PHASE1","title":"DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial","status":"NOT_YET_RECRUITING","sponsor":"Population Health Research Institute","isPivotal":false,"enrollment":100,"indication":"Atrial Fibrillation (AF), Stroke (in Patients With Atrial Fibrillation)","completionDate":"2027-06-03","primaryEndpoint":""},{"nctId":"NCT06429787","phase":"","title":"Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure","status":"RECRUITING","sponsor":"Octapharma","isPivotal":false,"enrollment":3574,"indication":"Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk","completionDate":"2032-06-30","primaryEndpoint":""},{"nctId":"NCT02798471","phase":"PHASE3","title":"Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","isPivotal":false,"enrollment":290,"indication":"Venous Thromboembolism (VTE), Pulmonary Embolism","completionDate":"2022-05-24","primaryEndpoint":""},{"nctId":"NCT03892824","phase":"NA","title":"Carotid Artery Implant for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Javelin Medical","isPivotal":false,"enrollment":100,"indication":"Atrial Fibrillation, Stroke","completionDate":"2027-10-24","primaryEndpoint":""},{"nctId":"NCT02618577","phase":"PHASE3","title":"Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes","status":"TERMINATED","sponsor":"Atrial Fibrillation Network","isPivotal":false,"enrollment":2608,"indication":"Atrial High Rate Episodes","completionDate":"2022-12-31","primaryEndpoint":""},{"nctId":"NCT06747312","phase":"PHASE2","title":"Effect of Belimumab on Antibody Titers in Primary APS Patients","status":"RECRUITING","sponsor":"Ruijin Hospital","isPivotal":false,"enrollment":20,"indication":"Antiphospholipid Syndrome (APS)","completionDate":"2027-05-31","primaryEndpoint":""},{"nctId":"NCT04062097","phase":"","title":"Registration of Idarucizumab for Patients with IntraCranial Hemorrhage","status":"COMPLETED","sponsor":"University Hospital, Essen","isPivotal":false,"enrollment":104,"indication":"Intracranial Hemorrhage","completionDate":"2021-12-31","primaryEndpoint":""},{"nctId":"NCT02886962","phase":"PHASE4","title":"Oral Anticoagulation in Haemodialysis Patients","status":"TERMINATED","sponsor":"University Hospital, Strasbourg, France","isPivotal":false,"enrollment":50,"indication":"Kidney Failure, Chronic","completionDate":"2023-12-01","primaryEndpoint":""},{"nctId":"NCT06143787","phase":"PHASE3","title":"Effect of TXA Oral Sol 5% in Patients Treated With DOACs or VKA and Undergoing a Single or Multiple Tooth Extraction","status":"UNKNOWN","sponsor":"Hyloris Developments","isPivotal":false,"enrollment":280,"indication":"Bleeding From Teeth, Bleeding Prophylaxis","completionDate":"2024-12-27","primaryEndpoint":""},{"nctId":"NCT04249401","phase":"","title":"Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":134897,"indication":"Atrial Fibrillation","completionDate":"2023-09-30","primaryEndpoint":""},{"nctId":"NCT04001205","phase":"","title":"Atrial Fibrillation Burden and Long-term Risk of Thromboembolic Complications- the FinCV-4 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Turku","isPivotal":false,"enrollment":1300,"indication":"Atrial Fibrillation, Stroke, Ischemic","completionDate":"2025-01-08","primaryEndpoint":""},{"nctId":"NCT05205863","phase":"PHASE1, PHASE2","title":"Dose-Response in PD and Safety of Cofact Under VKA Anticoagulation","status":"COMPLETED","sponsor":"Prothya Biosolutions","isPivotal":false,"enrollment":69,"indication":"Healthy Volunteers","completionDate":"2022-09-03","primaryEndpoint":""},{"nctId":"NCT06179823","phase":"","title":"Safety of Direct Oral Anticoagulant During Pregnancy","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","isPivotal":false,"enrollment":1755558,"indication":"Thromboembolic Disease","completionDate":"2020-12-31","primaryEndpoint":""},{"nctId":"NCT05150938","phase":"","title":"A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":5737,"indication":"Treatment of Venous Thromboembolism in Cancer Patients","completionDate":"2023-02-28","primaryEndpoint":""},{"nctId":"NCT03826927","phase":"","title":"New Oral Anticoagulants (NOAC) in Stroke Patients","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","isPivotal":false,"enrollment":1023,"indication":"Stroke, Atrial Fibrillation","completionDate":"2021-08","primaryEndpoint":""},{"nctId":"NCT02533960","phase":"","title":"Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime","status":"COMPLETED","sponsor":"University Hospital Heidelberg","isPivotal":false,"enrollment":3832,"indication":"Ischemic Stroke, Intracerebral Hemorrhage","completionDate":"2022-06","primaryEndpoint":""},{"nctId":"NCT04195113","phase":"","title":"Perioperative Anticoagulant Use for Surgery Evaluation Emergency Registry","status":"COMPLETED","sponsor":"McMaster University","isPivotal":false,"enrollment":242,"indication":"Atrial Fibrillation, Venous Thromboembolism","completionDate":"2022-12-31","primaryEndpoint":""},{"nctId":"NCT04002011","phase":"PHASE2","title":"DOAC Versus VKA After Cardiac Surgery","status":"WITHDRAWN","sponsor":"Laval University","isPivotal":false,"enrollment":0,"indication":"Anticoagulant-induced Bleeding","completionDate":"2023-03-09","primaryEndpoint":""},{"nctId":"NCT02740335","phase":"PHASE3","title":"Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.","status":"COMPLETED","sponsor":"Octapharma","isPivotal":false,"enrollment":208,"indication":"Significant Bleeding Risk","completionDate":"2022-02-23","primaryEndpoint":""},{"nctId":"NCT02353585","phase":"","title":"Novel Oral Anticoagulants in Stroke Patients","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","isPivotal":false,"enrollment":1050,"indication":"Ischemic Stroke, Intracranial Hemorrhages","completionDate":"2021-03","primaryEndpoint":""},{"nctId":"NCT02664155","phase":"PHASE3","title":"Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","isPivotal":false,"enrollment":203,"indication":"Renal Insufficiency","completionDate":"2022-05-30","primaryEndpoint":""},{"nctId":"NCT02832544","phase":"PHASE3","title":"INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority","status":"COMPLETED","sponsor":"Population Health Research Institute","isPivotal":false,"enrollment":4565,"indication":"Rheumatic Heart Disease","completionDate":"2022-08-18","primaryEndpoint":""},{"nctId":"NCT02981472","phase":"PHASE2","title":"A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":192,"indication":"Thrombosis","completionDate":"2021-10-18","primaryEndpoint":""},{"nctId":"NCT04171726","phase":"PHASE3","title":"Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation","status":"UNKNOWN","sponsor":"Erasmus Medical Center","isPivotal":false,"enrollment":100,"indication":"Aortic Valve Stenosis","completionDate":"2023-09-01","primaryEndpoint":""},{"nctId":"NCT02832531","phase":"PHASE3","title":"INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority","status":"WITHDRAWN","sponsor":"Population Health Research Institute","isPivotal":false,"enrollment":0,"indication":"Rheumatic Heart Disease","completionDate":"2022-08","primaryEndpoint":""},{"nctId":"NCT02663076","phase":"","title":"Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry","status":"COMPLETED","sponsor":"GWT-TUD GmbH","isPivotal":false,"enrollment":1700,"indication":"Non-valvular Atrial Fibrillation (NVAF), Chronic Kidney Disease (CKD)","completionDate":"2022-04-04","primaryEndpoint":""},{"nctId":"NCT02640222","phase":"","title":"APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":321501,"indication":"Anticoagulation","completionDate":"2019-12-31","primaryEndpoint":""},{"nctId":"NCT02507856","phase":"","title":"Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA","status":"COMPLETED","sponsor":"University Hospital, Essen","isPivotal":false,"enrollment":10044,"indication":"Brain Ischemia With Non-valvular Atrial Fibrillation, Transient Ischemic Attack With Non-valvular Atrial Fibrillation","completionDate":"2022-04","primaryEndpoint":""},{"nctId":"NCT02286414","phase":"","title":"Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","isPivotal":false,"enrollment":159,"indication":"Atrial Fibrillation","completionDate":"2021-11","primaryEndpoint":""},{"nctId":"NCT03362788","phase":"","title":"The Greek AntiPlatElet Atrial Fibrillation Registry.","status":"COMPLETED","sponsor":"Attikon Hospital","isPivotal":false,"enrollment":654,"indication":"Atrial Fibrillation, Coronary Artery Disease","completionDate":"2020-12-31","primaryEndpoint":""},{"nctId":"NCT02319460","phase":"","title":"An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding","status":"COMPLETED","sponsor":"CSL Behring","isPivotal":false,"enrollment":2238,"indication":"Hemorrhage","completionDate":"2020-06-30","primaryEndpoint":""},{"nctId":"NCT04099238","phase":"","title":"Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":3739,"indication":"Atrial Fibrillation","completionDate":"2020-07-16","primaryEndpoint":""},{"nctId":"NCT04518735","phase":"","title":"Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","isPivotal":false,"enrollment":1707,"indication":"Covid19","completionDate":"2020-06-30","primaryEndpoint":""},{"nctId":"NCT03150303","phase":"","title":"Oral Anticoagulant Peri-procedural Management in Patients Undergoing an Oral Surgery, Implantology or Periodontology","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","isPivotal":false,"enrollment":532,"indication":"Oral Anticoagulants, Invasive Procedure","completionDate":"2020-01-10","primaryEndpoint":""},{"nctId":"NCT03374540","phase":"","title":"Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":78517,"indication":"Nonvalvular Atrial Fibrillation","completionDate":"2019-08-30","primaryEndpoint":""},{"nctId":"NCT04419012","phase":"","title":"Polish Atrial Fibrillation (POL-AF) Registry","status":"UNKNOWN","sponsor":"Jan Kochanowski University","isPivotal":false,"enrollment":4000,"indication":"Atrial Fibrillation","completionDate":"2020-12-31","primaryEndpoint":""},{"nctId":"NCT03537521","phase":"","title":"Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists (RADOA). Focus on New Antidots","status":"WITHDRAWN","sponsor":"Cardioangiologisches Centrum Bethanien","isPivotal":false,"enrollment":0,"indication":"Severe Bleeding, Urgent Surgery","completionDate":"2023-04","primaryEndpoint":""},{"nctId":"NCT01722786","phase":"","title":"Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists","status":"COMPLETED","sponsor":"Cardioangiologisches Centrum Bethanien","isPivotal":false,"enrollment":272,"indication":"Severe Bleeding, Urgent Surgery","completionDate":"2019-07-09","primaryEndpoint":""},{"nctId":"NCT02415400","phase":"PHASE4","title":"A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":4614,"indication":"Acute Coronary Syndromes","completionDate":"2018-11-10","primaryEndpoint":""},{"nctId":"NCT02866175","phase":"PHASE3","title":"Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","isPivotal":false,"enrollment":1506,"indication":"Atrial Fibrillation","completionDate":"2019-06-06","primaryEndpoint":""},{"nctId":"NCT02596230","phase":"","title":"RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism","status":"COMPLETED","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":7797,"indication":"Venous Thromboembolism","completionDate":"2019-03-31","primaryEndpoint":""}],"_emaApprovals":[{"date":"","name":"Vitamin K antagonist (VKA)","status":"Authorised","regulator":"EMA"}],"molecularData":{"oral":false,"chemblId":"CHEMBL5308454","moleculeType":null,"molecularWeight":"430.72"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"04/21/2026","subject":"Feedback form"}],"_offLabelChecked":true,"publicationCount":804,"recentPublications":[{"date":"2026 Mar 30","pmid":"41910938","title":"Effectiveness of Four-Factor Prothrombin Complex Concentrate Versus Plasma in Patients on Vitamin K Antagonists Undergoing Urgent Orthopedic Surgery: A Post Hoc Analysis.","journal":"Advances in therapy"},{"date":"2026 Mar 16","pmid":"41834631","title":"Vitamin K antagonists and structural valve deterioration in bioprosthetic aortic valves.","journal":"Turk gogus kalp damar cerrahisi dergisi"},{"date":"2026 Apr 3","pmid":"41805281","title":"[Hemodialysis and VKAs: How INR self-monitoring and supervised administration during sessions improve anticoagulant treatment stability].","journal":"Nephrologie & therapeutique"},{"date":"2026 Feb 26","pmid":"41749338","title":"Intracranial hemorrhage after ischemic stroke in patients on direct oral anticoagulants: results from a prospective observational study.","journal":"Neurological research and practice"},{"date":"2026 Feb","pmid":"41668691","title":"One-Year Outcome of Japanese Patients With Atrial Fibrillation: Insights From APHRS-AF Registry.","journal":"Journal of arrhythmia"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"_genericFilersChecked":true,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"patents":[],"ownershipHistory":[],"biosimilars":[],"latestUpdates":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"preclinical","status":"active","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":9,"trialStats":{"total":56,"withResults":16},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-05-15T02:30:48.577578+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}